Evidence map›Paper›PMID 40124337›Full record

ArticleMaterials today. Bio2025

Purified bone xenografts: A novel and efficient animal bone substitute derived from an optimized supercritical CO

Solène Rota, Ludovic Sicard, Justine Perarnaud, Rémy Agniel, Raphaël Bardonnet, Catherine Chaussain, Michel Boissière, Emmanuel Pauthe, Caroline Gorin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Solène RotaERRMECe, Equipe de Recherche sur Les Relations Matrice Extracellulaire-Cellules (EA1391), Biomaterials for Health Research Group, Institut des Matériaux I-MAT (FD4122), CY Tech, CY Cergy Paris Université, Maison Internationale de la Recherche (MIR), rue Descartes, Neuville sur Oise cedex, France.
Ludovic SicardUniversité Paris Cité, URM1333 Oral Health Inserm, Dental School, Montrouge, France.
Justine PerarnaudERRMECe, Equipe de Recherche sur Les Relations Matrice Extracellulaire-Cellules (EA1391), Biomaterials for Health Research Group, Institut des Matériaux I-MAT (FD4122), CY Tech, CY Cergy Paris Université, Maison Internationale de la Recherche (MIR), rue Descartes, Neuville sur Oise cedex, France.
Rémy AgnielERRMECe, Equipe de Recherche sur Les Relations Matrice Extracellulaire-Cellules (EA1391), Biomaterials for Health Research Group, Institut des Matériaux I-MAT (FD4122), CY Tech, CY Cergy Paris Université, Maison Internationale de la Recherche (MIR), rue Descartes, Neuville sur Oise cedex, France.
Raphaël BardonnetBIOBank, Bone Tissue Bank, Lieusaint, France.
Catherine ChaussainUniversité Paris Cité, URM1333 Oral Health Inserm, Dental School, Montrouge, France.
Michel BoissièreERRMECe, Equipe de Recherche sur Les Relations Matrice Extracellulaire-Cellules (EA1391), Biomaterials for Health Research Group, Institut des Matériaux I-MAT (FD4122), CY Tech, CY Cergy Paris Université, Maison Internationale de la Recherche (MIR), rue Descartes, Neuville sur Oise cedex, France.
Emmanuel PautheERRMECe, Equipe de Recherche sur Les Relations Matrice Extracellulaire-Cellules (EA1391), Biomaterials for Health Research Group, Institut des Matériaux I-MAT (FD4122), CY Tech, CY Cergy Paris Université, Maison Internationale de la Recherche (MIR), rue Descartes, Neuville sur Oise cedex, France.
Caroline GorinUniversité Paris Cité, URM1333 Oral Health Inserm, Dental School, Montrouge, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone xenografts represent a promising alternative to autologous or allograft transplants, yet antigenicity in animal-derived tissues remains a major limitation to their clinical use. To provide any risk of contamination or allogenic rejection, the Supercrit® process was developed to treat allogeneic human bone combining a supercritical CO

Indexed as

AllograftBiocompatibilityBone regenerationBone substituteSupercritical fluidXenograft

Identifiers

PMID40124337
PMCPMC11930176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.